Thomas Charles McCarty

Title: Thomas Charles McCarty: Innovator in Respiratory Syncytial Virus Research

Introduction

Thomas Charles McCarty is a notable inventor based in Bethesda, MD (US). He has made significant contributions to the field of virology, particularly in the development of recombinant respiratory syncytial virus (RSV) strains. With a total of two patents to his name, McCarty's work focuses on enhancing vaccine efficacy through innovative genetic modifications.

Latest Patents

McCarty's latest patents include novel recombinant respiratory syncytial viruses that exhibit an attenuated phenotype. These viruses have undergone shifts in the native positions of the NS1 and/or NS2 genes within the RSV genome. The strategic repositioning of these genes, which are moved to more distal locations from the promoter, allows for desired levels of attenuation and immunogenicity. The recombinant RSV strains developed by McCarty are suitable for use as live-attenuated vaccines against RSV. Additionally, he has provided polynucleotide sequences capable of encoding these viruses, along with methods for their production and application.

Career Highlights

Thomas Charles McCarty is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to focus on groundbreaking research that has the potential to impact public health significantly.

Collaborations

One of McCarty's notable collaborators is Peter L. Collins. Their partnership has contributed to advancements in the understanding and treatment of respiratory syncytial virus.

Conclusion

Thomas Charles McCarty's innovative research in recombinant respiratory syncytial viruses exemplifies the critical role of inventors in advancing medical science. His contributions are paving the way for more effective vaccines and improved health outcomes.